Literature DB >> 11409696

Association of DRD4 with attention problems in normal childhood development.

L A Schmidt1, N A Fox, K Perez-Edgar, S Hu, D H Hamer.   

Abstract

Several previous studies found an association of clinically diagnosed attention deficit hyperactivity disorder with long alleles of a variation in the DRD4 dopamine receptor gene exon III coding sequence. We evaluated the DRD4 polymorphism in a non-clinically selected sample of children for whom maternal reports of attention problems were available at 4 and 7 years of age. There was a significant elevation in attention problem scores in children carrying DRD4 long alleles that accounted for 3-4% of total variation at each age and for 5-7% of the temporally stable component of the phenotype. Our results show that the DRD4 gene influences normal as well as pathological attention processes, and the results highlight the utility of longitudinal measurements in psychiatric genetics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409696     DOI: 10.1097/00041444-200103000-00005

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  21 in total

1.  A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q.

Authors:  S C Bakker; E M van der Meulen; J K Buitelaar; L A Sandkuijl; D L Pauls; A J Monsuur; R van 't Slot; R B Minderaa; W B Gunning; P L Pearson; R J Sinke
Journal:  Am J Hum Genet       Date:  2003-04-04       Impact factor: 11.025

2.  Anger/frustration, task persistence, and conduct problems in childhood: a behavioral genetic analysis.

Authors:  Kirby Deater-Deckard; Stephen A Petrill; Lee A Thompson
Journal:  J Child Psychol Psychiatry       Date:  2007-01       Impact factor: 8.982

3.  Dopamine D4 receptor gene variation is associated with context-dependent attention for emotion stimuli.

Authors:  Tony T Wells; Christopher G Beevers; Valerie S Knopik; John E McGeary
Journal:  Int J Neuropsychopharmacol       Date:  2012-05-21       Impact factor: 5.176

4.  Gene-environment interaction between dopamine receptor D4 7-repeat polymorphism and early maternal sensitivity predicts inattention trajectories across middle childhood.

Authors:  Daniel Berry; Kirby Deater-Deckard; Kathleen McCartney; Zhe Wang; Stephen A Petrill
Journal:  Dev Psychopathol       Date:  2013-05

5.  Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population.

Authors:  M V Alfimova; V E Golimbet; I K Gritsenko; T V Lezheiko; L I Abramova; M A Strel'tsova; I V Khlopina; R Ebstein
Journal:  Neurosci Behav Physiol       Date:  2007-09

Review 6.  Cognitive neuroscience of Attention Deficit Hyperactivity Disorder: current status and working hypotheses.

Authors:  Chandan J Vaidya; Melanie Stollstorff
Journal:  Dev Disabil Res Rev       Date:  2008

Review 7.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

8.  Infant genotype may moderate sensitivity to maternal affective communications: attachment disorganization, quality of care, and the DRD4 polymorphism.

Authors:  Judit Gervai; Alexa Novak; Krisztina Lakatos; Ildiko Toth; Ildiko Danis; Zsolt Ronai; Zsofia Nemoda; Maria Sasvari-Szekely; Jean-Francois Bureau; Elisa Bronfman; Karlen Lyons-Ruth
Journal:  Soc Neurosci       Date:  2007       Impact factor: 2.083

9.  Linking gene, brain, and behavior: DRD4, frontal asymmetry, and temperament.

Authors:  Louis A Schmidt; Nathan A Fox; Koraly Perez-Edgar; Dean H Hamer
Journal:  Psychol Sci       Date:  2009-06-01

10.  Dopaminergic variants in siblings at high risk for autism: Associations with initiating joint attention.

Authors:  Devon N Gangi; Daniel S Messinger; Eden R Martin; Michael L Cuccaro
Journal:  Autism Res       Date:  2016-03-15       Impact factor: 5.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.